Lymphoma, Large B-Cell, Diffuse: all 1,432 studies

Page 1 of 15. Open to participants first (359), then studies with results posted, then the rest; newest registration first within each.

• Natalizumab for the Prevention of ICANS in Patients With Recurrent or Refractory Diffuse Large B-Cell Lymphoma or Mantle Cell Lymphoma Receiving CAR T-Cell TherapyRecruitingNCT07892027Phase 2
• REGN9220 in Combination With Odronextamab in Adult Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphomas (BCNHLs)Not yet recruitingNCT07887750Phase 1/2
• A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0920 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell MalignanciesNot yet recruitingNCT07887646Phase 1
• Phase I Safety Clinical Trial of Anti-CD19 CAR-T Therapy COL01 for the Treatment of Adults With Relapsed or Refractory B-cell Lymphoid Neoplasms: First-in-human Administration, COLIBRI.Not yet recruitingNCT07883941Phase 1
• A Study Investigating the Safety and How the Trispecific T-Cell Engaging Antibody BG-T0050 Works in Adults With Diffuse Large B-cell Lymphoma (DLBCL) and Other Aggressive B-Cell MalignanciesNot yet recruitingNCT07881211Phase 1
• Prospective ctDNA Testing in Large B-Cell LymphomaRecruitingNCT07878351
• Prizloncabtagene Autoleucel (Prizlon-cel) for the Treatment of Relapsed or Refractory Large B-cell Lymphoma Post FDA Approved CAR T-cell TherapyNot yet recruitingNCT07875413Phase 2
• A Study to Assess Change in Disease State and Adverse Events in Korean Adult Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) or Follicular Lymphoma (FL) Receiving Epcoritamab InjectionsNot yet recruitingNCT07862764
• A Study of BL-M08D1 in Combination With Immunochemotherapy in Patients With Diffuse Large B-Cell LymphomaNot yet recruitingNCT07818499Phase 1/2
• Proton Therapy for Mediastinal Lymphoma (PROMLY)RecruitingNCT07817641Not applicable
• Epcoritamab Plus Lenalidomide in Relapsed/Refractory Large B-cell Lymphoma After Second-Line CAR T-cell TherapyNot yet recruitingNCT07814001Phase 2
• A Randomized, Open-Label, Multicenter Phase III Clinical Study of JS203 Plus Chemotherapy Versus Rituximab Plus Chemotherapy in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07808827Phase 3
• Tumour Immune and Ki-67 Scoring Methods as Prognostic Biomarkers in Diffuse Large B-cell Lymphoma and Aggressive B-cell LymphomasNot yet recruitingNCT07804173
• A Phase Ib/II Exploratory Clinical Trial of Memory-Enhanced 7×19-THEMIS CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell LymphomaRecruitingNCT07788118Phase 1/2
• Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell LymphomaNot yet recruitingNCT07774234Phase 2
• R-MA-PD-1 Versus R-MA in Treatment-naive Primary CNS LymphomaNot yet recruitingNCT07764601Not applicable
• Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaRecruitingNCT07763210Phase 2
• Pomalidomide Plus Rituximab Maintenance in Young High-Risk Newly Diagnosed DLBCL After First-Line ResponseNot yet recruitingNCT07760610Phase 4
• Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)RecruitingNCT07750886
• GRACE: A Phase 1/2a Study of VTRU200 in Relapsed/Refractory AML, High-risk MDS, DLBCL Post CART Failure and Advanced Solid TumorsNot yet recruitingNCT07749976Phase 1/2
• Glofitamab in B-NHL Using Mid-Therapy Intratumoral TranscriptomicsNot yet recruitingNCT07748364Phase 2
• A Phase 1/2 Study of UB-VV400 With Rapamycin in Relapsed/Refractory B-cell MalignanciesRecruitingNCT07735533Phase 1/2
• Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)Not yet recruitingNCT07729397Phase 1
• Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple MyelomaNot yet recruitingNCT07725406Phase 1
• Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymphoma in Elderly or Unfit PatientsNot yet recruitingNCT07714421Phase 1
• A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNot yet recruitingNCT07713459Phase 2
• Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)Not yet recruitingNCT07712588Phase 2/3
• A Study of Polatuzumab Vedotin and Glofitamab in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma Within 12 Months After R-CHOPNot yet recruitingNCT07702851Phase 2
• A Study of ARC-02 in B-cell NHLRecruitingNCT07691606Phase 1
• Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell LymphomaRecruitingNCT07676877Phase 1
• Glofitamab Combined With Selinexor in Patients With Relapsed/Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07669194
• The CARDIOPROTECT TrialRecruitingNCT07654426Phase 2
• Neurocognitive Assessment in Long-Term Survivors of LymphomaNot yet recruitingNCT07652476
• AMC 120, Glofitamab Plus Chemoimmunotherapy in Newly Diagnosed HIV-Associated Large B-Cell Lymphoma (The "Glofit-RCHOP Study")Not yet recruitingNCT07649304Phase 1
• Axatilimab + CAR-T for High-Risk LymphomaNot yet recruitingNCT07638982Phase 1
• Radiotherapy in Combination With Glofitamab in Relapsed/Refractory Diffuse Large B Cell LymphomaNot yet recruitingNCT07634289Phase 2
• A Study of Rocbrutinib in Combination With Lacutoclax in Patients With B-Cell MalignanciesRecruitingNCT07609862Phase 1/2
• Efficacy and Safety of Polatuzumab Vedotin in Combination With Zanubrutinib, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone in Patients With Previously Untreated Diffuse Large B-Cell Lymphoma of the MCD/BN2/N1 SubtypesRecruitingNCT07608978Phase 2
• Lisaftoclax Plus Chidamide and Rituximab in Relapsed or Refractory Diffuse Large B-cell LymphomaNot yet recruitingNCT07601607Phase 1/2
• A Study of Glofitamab Plus GemOx Compared With Standard of Care in Patients With Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07599423Phase 2
• Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin LymphomaNot yet recruitingNCT07588698Phase 2
• A Phase Ⅰ Study of CS08399 in Participants With MTAP-deleted Solid Tumors and LymphomaNot yet recruitingNCT07583771Phase 1
• Phase I Clinical Study on the Safety and Efficacy of CY-219 CAR-T Cell Injection in the Treatment of Relapsed/Refractory B-Cell LymphomaNot yet recruitingNCT07539688Phase 1
• External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCLRecruitingNCT07528352Phase 1
• Pomalidomide, Anti-PD-1 Antibody Combined With Selinexor (PPS) in Relapsed/Refractory Primary Central Nervous System Diffuse Large B-Cell LymphomaRecruitingNCT07523737Phase 2
• A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)RecruitingNCT07519772Phase 1/2
• MRD-Adapted Low-Dose Radiation Therapy During Frontline Chemoimmunotherapy for Diffuse Large B-Cell LymphomaNot yet recruitingNCT07517705Phase 2
• Chidamide Maintenance for MRD-Positive Double-Expressor DLBCL in First Complete RemissionRecruitingNCT07507318Phase 2
• TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell LymphomaNot yet recruitingNCT07502872Phase 2
• NexCAR19 (Talikabtagene Autoleucel) in Relapsed/Refractory B-Cell Malignancies (NexCAR19)RecruitingNCT07502118Phase 2/3
• Genetic Subtype-matched Targeted Therapy for the Treatment of Newly Diagnosed DLBCL With TP53 MutationRecruitingNCT07499271Phase 2
• Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCLRecruitingNCT07494565Phase 2
• Chidamide Combination With R-mini CHOP Followed by Chidamide+CD20 Maintenance in Elderly Newly Diagnosed MYC/BCL2+ DLBCLRecruitingNCT07493148Phase 2
• Chidamide for Maintenance Treatment of HBV-infected Diffuse DLBCL in Patients Initially Treated With R-CHOPRecruitingNCT07493109Phase 3
• Enhancing CAR-T Cell Therapy Efficacy in B-cell Lymphoma Via Chidamide and PD-1 Inhibitor Combination.RecruitingNCT07489989Phase 2
• Radiation, Oral Vancomycin, and CAR-T for B-Cell LymphomasRecruitingNCT07478848Phase 1
• Geriatric-guided Care Versus Conventional Care in Elderly Unfit/Frail Patients With Diffuse Large B-cell Lymphoma in First Line TreatmentNot yet recruitingNCT07476105Not applicable
• Study of Safety and Efficacy of TC011 in the Relapsed/Refractory Large B Cell Non-Hodgkin Lymphoma PatientsRecruitingNCT07473167Phase 1/2
• Neurocognitive Assessment in Adults Undergoing CD19 Targeted CAR-T Cell TherapyNot yet recruitingNCT07463781
• Low Dose Epcoritamab Plus GemOx in R/R DLBCLRecruitingNCT07451652Phase 2
• Cognitive Impairment in Patients With Diffuse Large B-Cell LymphomaRecruitingNCT07443514Not applicable
• A Study of APG-3288 in Relapsed/Refractory Blood CancersRecruitingNCT07424833Phase 1
• This Clinical Trial is a Single-arm, Non-randomized Pilot Trial to Determine the Safety of Administering Autologous Anti-C19 Cells (ARI-0001) and the Feasibility of Local CAR-T Cell Production in Patients Over 18 Years of Age With Relapsed/Refractory (R/R) CD19+ Hematologic Malignancies, Including RNot yet recruitingNCT07412405Not applicable
• A Phase III Study of HMPL-760 Plus R-GemOx VS Placebo Plus R-GemOx in Relapsed/Refractory DLBCLRecruitingNCT07409428Phase 3
• Lisatoclax Plus R-CHOP or Pola-R-CHP in Untreated DLBCL: A Phase Ib/II StudyNot yet recruitingNCT07398638Phase 1/2
• CRP Regimen in Treating Elderly Patients With Previously Untreated Double-Positive DLBCLRecruitingNCT07397832Phase 2
• Application of Zanubrutinib-based Combination Regimens in the Treatment of Newly-diagnosed Diffuse Large B-cell LymphomaRecruitingNCT07371923Phase 2
• Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell LymphomaRecruitingNCT07368270Phase 1
• Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07365306Phase 2
• A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell LymphomaEnrolling by invitationNCT07348575Phase 3
• Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination TherapyNot yet recruitingNCT07310186
• Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT07284433Phase 1/2
• KSV01 Injection for the Treatment of Relapsed/Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07260812Phase 1
• Study to Evaluate the Efficacy of Axicabtagene Ciloleucel in Patients With Late Relapse of Diffuse Large B-Cell LymphomaRecruitingNCT07254754Phase 2
• A Study of LY4584180 in Adult Participants With Previously Treated Blood CancersRecruitingNCT07226843Phase 1
• Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT07225439Phase 1
• Karyopharm Expanded Access Program for SelinexorAvailableNCT07215832
• An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell LymphomaRecruitingNCT07200375
• Drug-Eluting Bead-Based Transarterial Chemoembolization (DEB-TACE) as a Local Salvage Therapy for Large Lesions in Relapsed and Refractory Diffuse Large B-Cell LymphomaRecruitingNCT07198230
• Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)RecruitingNCT07197307Phase 2
• A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological MalignanciesRecruitingNCT07195916Phase 1
• A Study of Rocbrutinib in Participants With Relapse or Refractory Non-GCB Diffuse Large B-Cell LymphomaRecruitingNCT07189065Phase 2
• A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell TherapyRecruitingNCT07188558Phase 3
• Metabolic and Immunomic Differential Analysis of Primary Central Nervous System Diffuse Large B-Cell LymphomaRecruitingNCT07188077
• CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasEnrolling by invitationNCT07168486Phase 1
• Novel Bispecific AbTCR (Anti-CD19/CD22)-T Cells in Relapsed or Refractory B-cell LymphomaNot yet recruitingNCT07168291Early Phase 1
• Homoharringtonine, BCL-2 Inhibitor, Rituximab, and Prednisone in Relapsed/Refractory Diffuse Large B-Cell LymphomaNot yet recruitingNCT07159906Phase 1/2
• Response-adaptive to Epcoritamab In First Relapse: Study to Evaluate the Efficacy of Eptoritamab in Patients With Relapse/Refractory Large B Cell LymphomaRecruitingNCT07126236Phase 2
• A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell LymphomaRecruitingNCT07124936Phase 1/2
• A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )RecruitingNCT07101328Phase 1
• Epcoritamab With Dose Adjusted Etoposide, Cyclophosphamide, Vincristine, Doxorubicin, Prednisone and Rituximab (EPOCH-R) for the Treatment of Aggressive B-Cell Non-Hodgkin LymphomaRecruitingNCT07097363Phase 2
• Xinlikang Capsule for Chemotherapy-induced Fatigue and Immune Disorders in Diffuse Large B LymphomaRecruitingNCT07084662Phase 2/3
• Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell LymphomaRecruitingNCT07078500Phase 2
• Relmacabtagene Autoleucel Combined With Sintilimab for Relapsed/Refractory B-cell LymphomaRecruitingNCT07077512Phase 2
• Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCLRecruitingNCT07072208Not applicable
• Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PETRecruitingNCT07070648
• Anbalcabtagene Autoleucel in Relapsed/Refractory CNS LymphomaRecruitingNCT07062627Phase 2
• DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12)RecruitingNCT07059650Phase 1/2
• Fecal Microbiome Transplant to Remodel Intestinal Microbiota for Patients With Relapsed or Refractory Lymphoma With Exposure to High-Risk Antibiotics Who Are Receiving Chimeric Antigen Receptor T CellsRecruitingNCT07042438Phase 2
• A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCLNot yet recruitingNCT07035379Phase 1/2

← Lymphoma, Large B-Cell, Diffuse overview